FRONTIER CAPITAL MANAGEMENT CO LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 351173
Boston, MA
Position in HALO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$26,812,953
-$45,871,944 QoQ
Shares Held
342,570
-73.0% QoQ
Ownership
0.302%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
#70
of 667 holders
Holding Since
Jun 2023
7 quarters on record
Voting authority
Sole 66%
Shared 0%
None 34%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FRONTIER CAPITAL MANAGEMENT CO LLC holds $975,847,387 across 22 Biotechnology names. HALO ranks #13 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,373,057 | $102,265,285 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,847,936 | $95,092,583 | |
| 3 | KYMR |
Kymera Therapeutics, Inc.
|
740,866 | $84,955,104 | |
| 4 | INSM |
INSMED Inc
|
795,242 | $84,788,702 | |
| 5 | PVLA |
Palvella Therapeutics, Inc.
|
478,833 | $73,175,259 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
277,279 | $66,815,920 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
254,280 | $62,240,115 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
3,070,740 | $57,269,301 |
All Filings in HALO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $26,812,953 | 342,570 | Shares | Sole | 2026-08-14 | |
| 2024-09-30 | $72,684,897 | 1,269,827 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $44,308,445 | 846,227 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $9,927,262 | 244,033 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $6,555,780 | 177,375 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $6,765,296 | 177,102 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $1,639,706 | 45,459 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||